Adam Feuerstein

Before joining TheStreet in March 2001, Feuerstein covered business software for Upside.com. Prior to that he covered a variety of business beats, including technology and commercial real estate, at the San Francisco Business Times.

 


Feuerstein graduated from Emory University with a bachelor's degree in political science.

 


Recent Articles By The Author

Nektar Addiction-Resistant Opioid Reduces Chronic Pain in Late-Stage Study

Nektar Addiction-Resistant Opioid Reduces Chronic Pain in Late-Stage Study

Nektar plans to out-license the experimental opioid NKTR-181 to a partner for continued development.

Amgen Cholesterol Drug Cuts Risk of Heart Attack, Stroke but Not Enough to Quell Value Debate

Amgen Cholesterol Drug Cuts Risk of Heart Attack, Stroke but Not Enough to Quell Value Debate

Is Repatha's $14,000 price tag justified by the magnitude of the drug's benefit to patients, measured by a lower risk of heart attacks and strokes?

PTC Therapeutics Snags Duchenne Steroid and Price-Gouging Albatross from Marathon Pharma

PTC Therapeutics Snags Duchenne Steroid and Price-Gouging Albatross from Marathon Pharma

PTC Therapeutics already sells a drug for Duchenne muscular dystrophy that does not work. Now, the drug maker is buying a second, approved Duchenne drug mired in a price-gouging controversy.

AstraZeneca Takes PARP Inhibitor Fight to Rival Tesaro with Strong Ovarian Cancer Study Results

AstraZeneca Takes PARP Inhibitor Fight to Rival Tesaro with Strong Ovarian Cancer Study Results

AstraZeneca's PARP inhibitor Lynparza delayed the recurrence of ovarian cancer by more than two years compared to a placebo.

Allergan, Editas Sign Gene-Editing Pact for Rare Eye Diseases

Allergan, Editas Sign Gene-Editing Pact for Rare Eye Diseases

The deal announced Tuesday gives Allergan exclusive access to five Editas programs aimed at serious, inherited eye diseases.